English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18076/20274 (89%)
造訪人次 : 4613549      線上人數 : 795
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/33549


    標題: 治療/照影雙功能前驅藥物作為癌症的精確診斷和標靶治療( I )
    Theranostics Combining Cancer Precision Diagnosis and Targeted Therapy( I )
    作者: 呂玉玲
    貢獻者: 嘉藥學校財團法人嘉南藥理大學藥學系(含碩士班)
    關鍵字: 前驅藥物
    葡萄醣醛酸?
    近紅外光
    精確診斷和標靶治療
    prodrug
    Beta-glucuronidase
    Near-IR
    precise diagnosis target therapy
    日期: 2020
    上傳時間: 2022-01-13 16:19:59 (UTC+8)
    摘要: 目前全世界正進入精確和個性化醫學的時代,根據每個患者的需求量身定製藥物,然後將藥物選擇性的遞送給病灶處,但不傷害健康的細胞。在癌症治療中,為達到精準治療的有效策略是依據腫瘤細胞特定的酵素,將治療劑或顯像劑與標靶基質連接來設計前驅藥物,前驅藥物將可以選擇性水解在病理細胞。葡萄醣醛酸?(β-glucuronidase, βG)是重要的腫瘤標記。因腫瘤處具有較高的βG活性,開發可同時被葡萄醣醛酸?(-glucuronidase, G)調控(off/on)之治療/照影雙功能前驅藥物Glu-NIRoff-Prodrug,利用抗腫瘤藥物的發色團, 應用photo-induce proton transfer(PET)原理焠熄近紅外光訊號,使治療/照影雙功能前驅藥物Glu-NIRoff-Prodrug具有低背景的優勢,表現出微不足道的細胞毒性和非常弱的螢光,在G專一性活化後, 前驅藥物由分子釋出有活性的抗腫瘤藥物, 也失去質子轉移焠熄近紅光訊號的作用, 才可再散發近紅外光訊號。因此,可用於標靶策略的腫瘤治療和即時偵測活體內腫瘤G活性,以便即時造影評估葡萄糖酸?前驅抗癌藥物的治療效果。創新開發同時治療和照影的前驅藥物, 可作為癌症的精確診斷和標靶治療。
    The world is now entering the era of precision and personalized medicine, where drugs will be tailored for each patient’s needs and then delivered specifically to diseased but not normal cells. In cancer treatment. One attractive strategy for achieving the desired pathologic cell is prodrug. The prodrug specificity is to link an established therapeutic or imaging agent to a targeting substrate, it can hydrolysis selectively in the pathologic cell. Beta-glucuronidase (G) is a tumor biomarker. Because of the high βG activity at the tumor site, its potential biomarker for cancer diagnosis and prodrug therapy. Development theranostics (Glu-NIRoff-Prodrug) via G off/on that combining cancer precision diagnosis and targeted therapy. Antitumor drugs as chromophore, using photo-induce proton transfer (PET) principle to quench near-infrared light signals. Thus, Glu-NIRoff-Prodrug has the advantage of a low background, shows negligible cytotoxicity and very weak fluorescence. After G specific activation, Glu-NIRoff-Prodrug release active antitumor drugs from molecule, it also loses the role of proton transfer to quench the near red light signal, then the near infrared light signal be emitted. Therefore, Glu-NIRoff-Prodrug can be used for target tumor treatment and real-time detection of tumor G activity in vivo. Immediate angiography to evaluate the therapeutic effect of glucuronide anticancer drugs. Innovative development of Glu-NIRoff-Prodrug that simultaneously treat and illuminate, can be used as a precise diagnosis and target treatment for cancer.
    關聯: 計畫編號:MOST109-2622-B041-001-CC1
    計畫年度:109
    執行起迄:2020-06~2021-05
    顯示於類別:[藥學系(所)] 科技部計畫

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    1092622B041001CC1(第1年).pdf553KbAdobe PDF305檢視/開啟
    index.html0KbHTML1154檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋